
## Kiyoshi takasuna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3287/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reliable identification of cardiac conduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening environment. Journal of Pharmacological and Toxicological Methods, 2021, 112, 107125.	0.7	6
2	Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment. Journal of Pharmacological and Toxicological Methods, 2020, 105, 106884.	0.7	15
3	Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety) Tj ETQq1 1 0.784	314 rgBT / 1.6	Overlock 1
4	Electrophysiological evaluation of pentamidine and 17-AAG in human stem cell-derived cardiomyocytes for safety assessment. European Journal of Pharmacology, 2019, 842, 221-230.	3.5	11
5	On-chip spatiotemporal electrophysiological analysis of human stem cell derived cardiomyocytes enables quantitative assessment of proarrhythmia in drug development. Scientific Reports, 2018, 8, 14536.	3.3	17
6	Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative. Journal of Pharmacological and Toxicological Methods, 2017, 83, 42-54.	0.7	50
7	On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Scientific Reports, 2015, 4, 4670.	3.3	42
8	Availability of intracellular Ca2+ imaging using iPS-induced cardiomyocytes as a new cardiac toxicity assessment. Journal of Pharmacological and Toxicological Methods, 2015, 75, 199.	0.7	1
9	Pre-clinical QT Risk Assessment in Pharmaceutical Companies - Issues of Current QT Risk Assessment Biomolecules and Therapeutics, 2009, 17, 1-11.	2.4	14